Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Int J Gynecol Cancer. 2013 Jun;23(5):964-70. doi: 10.1097/IGC.0b013e3182954da8.
To describe the incidence of low-volume ultrastage-detected metastases in sentinel lymph nodes (SLNs) identified at surgical staging for endometrial carcinoma and to correlate it with depth of myoinvasion and tumor grade.
We reviewed all patients who underwent primary surgery for endometrial carcinoma with successful mapping of at least one SLN at our institution from September 2005 to December 2011. All patients underwent a cervical injection for mapping. The SLN ultrastaging protocol involved cutting an additional 2 adjacent 5-μm sections at each of 2 levels, 50-μm apart, from each paraffin block lacking metastatic carcinoma on routine hematoxylin and eosin (H&E) staining. At each level, one slide was stained with H&E and with immunohistochemistry (IHC) using anticytokeratin AE1:AE3.Micrometastases (tumor deposits >0.2 mm and ≤2 mm) and isolated tumor cells (≤0.2 mm) were classified as low-volume ultrastage-detected metastases if pathologic ultrastaging was the only method allowing detection of such nodal disease.
Of 508 patients with successful mapping, 413 patients (81.3%) had endometrioid carcinoma. Sixty-four (12.6%) of the 508 patients had positive nodes: routine H&E detected 35 patients (6.9%), ultrastaging detected an additional 23 patients (4.5%) who would have otherwise been missed (4 micrometastases and 19 isolated tumor cells), and 6 patients (1.2%) had metastatic disease in their non-SLNs. The incidence rates of low-volume ultrastage-detected nodal metastases in patients with grades 1, 2, and 3 tumors were 3.8%, 3.4%, and 6.9%, respectively. The frequency rates of low-volume ultrastage-detected metastases in patients with a depth of myoinvasion of 0, less than 50%, and 50% or more were 0.8%, 8.0%, and 7.4%, respectively. Lymphovascular invasion was present in 20 (87%) of the cases containing low-volume ultrastage-detected metastases in the lymph nodes.
Sentinel lymph node mapping with pathologic ultrastaging in endometrial carcinoma detects additional low-volume metastases (4.5%) that would otherwise go undetected with routine evaluations. Our data support the incorporation of pathologic ultrastaging of SLNs in endometrial carcinoma with any degree of myoinvasion. The oncologic significance of low-volume nodal metastases requires long-term follow-up.
描述在子宫内膜癌的外科分期中,通过手术发现的前哨淋巴结 (SLN) 中超微阶段检测到的低体积转移的发生率,并将其与肌层浸润深度和肿瘤分级相关联。
我们回顾了 2005 年 9 月至 2011 年 12 月期间在我院接受子宫内膜癌初次手术且至少成功定位了一个 SLN 的所有患者。所有患者均接受了宫颈注射以进行定位。SLN 超微阶段检测方案包括在每个无常规苏木精和伊红 (H&E) 染色转移癌的石蜡块上,从每个 50μm 间隔的 2 个水平上额外切割 2 个相邻的 5μm 切片。在每个水平上,一个切片用 H&E 染色,一个切片用抗细胞角蛋白 AE1:AE3 的免疫组织化学 (IHC) 染色。微转移(肿瘤沉积 >0.2mm 且 ≤2mm)和孤立肿瘤细胞(≤0.2mm)被归类为低体积超微阶段检测到的转移,如果仅通过病理超微阶段检测才能发现这种淋巴结疾病,则分类为低体积超微阶段检测到的转移。
在 508 例成功定位的患者中,有 413 例(81.3%)为子宫内膜样癌。64 例(12.6%)患者的淋巴结呈阳性:常规 H&E 检测到 35 例(6.9%),超微阶段检测到另外 23 例(4.5%)会被遗漏的患者(4 例微转移和 19 例孤立肿瘤细胞),而 6 例(1.2%)患者的非 SLN 中有转移性疾病。1 级、2 级和 3 级肿瘤患者的低体积超微阶段检测到的淋巴结转移发生率分别为 3.8%、3.4%和 6.9%。肌层浸润深度为 0、<50%和≥50%的患者中,低体积超微阶段检测到的转移的频率分别为 0.8%、8.0%和 7.4%。在包含淋巴结中低体积超微阶段检测到的转移的 20 例(87%)病例中,存在脉管侵犯。
在子宫内膜癌中,使用 SLN 病理超微阶段检测可检测到更多的低体积转移(4.5%),否则这些转移将无法通过常规评估检测到。我们的数据支持在任何程度肌层浸润的子宫内膜癌中纳入 SLN 的病理超微阶段检测。低体积淋巴结转移的肿瘤学意义需要长期随访。